Evaluation of the ventricular assist device programme in the UK

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS,...

Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation

“…24 A detailed description of resource use data and unit cost estimates can be found in the original article 23 and associated Health Technology Assessment report. 1 Briefly, data were collected for surgical procedure and subsequent stay in the intensive care unit (ICU) and cardiac ward, HT assessment, HT procedure and associated ICU and ward stay, follow-up readmissions to the ICU or ward, outpatient visits, investigations, blood tests, and drugs. Resource use data were also collected for all adverse events.…”

“…1 As a result of the high mortality rate associated with conventional therapy while awaiting HT, which is mainly pharmacologic with intravenous inotropic agents, left ventricular assist devices (LVADs) have been proposed as a life-saving alternative for patients with hemodynamic decompensation. [2][3][4] In 2008, the United States (US) Food and Drug Administration (FDA) approved the LVAD HeartMate II 5 (Thoratec Corp, Pleasanton, CA) for use as a bridge to HT (BTT) in candidates at risk of imminent death from non-reversible LV failure.…”

Preliminary report on the cost effectiveness of ventricular assist devices

“…Although there are some reports of related studies, the cost effectiveness of VAD implantation surgery for end-stage heart failure [5][6][7][8][9] has not been sufficiently evaluated in the context of the medical system of certain counties. In particular, there is a need for a comparative economic evaluation of extracorporeal and implantable VADs and a socioeconomic evaluation of long-term use of VADs.…”

Cost-Effectiveness Analysis of Cardiovascular Disease Treatment in Japan

“…46) Another meta-analysis showed an ICER of $89,790-$414,274 per QALY for LVAD over heart transplantation for end-stage heart failure. 47) These data suggested that LVAD is not cost-effective for endstage heart failure.…”